Acadia Pharmaceuticals Inc., of San Diego, received patent No. 5,707,798, titled "Identification of ligands by selective amplification of cells transfected with receptors." The patent covers its receptor selection and amplification technology (r-SAT), which identifies lead compounds for drug development and for the characterization of drug targets. R-SAT is a platform of cell-based technologies that allows for functional analysis of recombinant therapeutic targets.
Alfacell Corp., of Bloomfield, N.J. received patent No. 5,728,805, covering a family of variants of Onconase, an antitumor agent, including other ribonucleases related to Onoconase.
Alliance Pharmaceutical Corp., of San Diego, received patent No. 5,733,527, titled "Improved Methods for Harmonic Imaging with Ultrasound." The patent covers methods of harmonic imaging using "second generation" microbubble contrast agents.
American Biogenetic Sciences Inc., of Copiague, N.Y., was granted patent No. 5,723,126, titled "Method and Compositions for Therapeutic Uses of a Fibrin-Specific Monoclonal Antibody." The patent covers a method of utilizing the company's fibrin-specific monoclonal antibody (MH-1) as a site-specific vehicle to deliver clot dissolving drugs.
Angiotech Pharmaceuticals Inc., of Vancouver, British Columbia, received a patent for use of paclitaxel-coated stents in the treatment of vascular obstructions.
ArQule Inc.,of Medford, Mass., received patent No. 5,712,171, titled, "Method of Generating a Plurality of Compounds in a Spatially Arranged Array." The technology is designed to reduce the time required to identify and optimize potential drug candidates to under two years. The industry standard is six years. ArQule also received patent No. 5,734,082, titled, "Hydroxyethyl Aminimides," which covers the hydroxyethyl variant of aminimide structures.
BioTransplant Inc., of Charlestown, Mass., and MedImmune Inc., of Gaithersburg, Md., received patent No. 5,730,979, for the companies' antibodies, BTI-322 and MEDI-507, both of which inhibit T cell mediated immune responses and selectively target specific immune cells believed responsible for organ rejection, graft-vs.-host disease and certain autoimmune diseases.
Cadus Pharmaceutical Corp., of Tarrytown, N.Y., received patent No. 5,739,029, covering the company's core yeast technology. In addition, Cadus received notices of allowance on two patent applications related to the company's self-selecting combinatorial library technology.
Cellegy Pharmaceuticals Inc., of Foster City Calif., received two notices of allowances for its drug delivery technologies designed to ease the transdermal and topical delivery of a number of drugs to treat systemic and skin diseases. The two technologies are part of Cellegy's Permeate drug delivery system.
Commonwealth Biotechnologies Inc., of Richmond, Va., received notice of allowance on a patent covering new heparin-binding petptide compounds, which are designed to reverse the anticoagulant effects of heparin during cardiovascular surgery.
Cypress Bioscience Inc., of San Diego, received a notice of allowance for its patent applications concerning the use of its Prosorba column in the treatment of rheumatoid arthritis (RA) and idiopathic thrombocytopenic purpura, an immune-mediated bleeding disorder. The patents cover the current FDA-approved use of the Prosorba column as well as the RA indication for which the company intends to seek approval this year.
Cypros Pharmaceutical Corp., of Carlsbad, Calif., received a patent on all claims covering the use of fructose-1, 6-diphosphate (FDP) for the treatment of asthma. FDP is the active ingredient in the Cypros drug Cordox (formerly CPC-111). The patent covers both inhaled and intravenous methods of taking Cordox. The company also received an exclusive license from the University of Rhode Island for patent No. 5,703,084, covering a series of compounds that can selectively raise adenosine levels in ischemic tissues, which then helps the body's natural defenses. Adenosine is a naturally occurring cytoprotective agent that reduces tissue damage in heart and brain ischemia as well as inflammation.
Desmos Inc., of San Diego, Calif., received two patents in the field of islet cell transplantation for diabetes therapy. The company's patents offer potential improvements to the transplantation of human and non-human materials for its research. The patents are: No. 5,681,587, titled "Growth of Adult Pancreatic Islet Cells," and No. 5,672,361, "Laminin-5 Growth of Pancreatic Islet Cells."
Diagnostic Products Corp., of Los Angeles, received a patent related to the company's ImmuGold system, a point-of-care diagnostic instrument designed to provide results in less than five minutes for medically important blood chemistry tests. Slated for a 1999 market introduction, the ImmuGold system can quickly measure cardiac markers, cancer markers, antibodies, hormones, therapeutic compounds, drugs of abuse and other substances at infinitesimally small concentrations.
Dianon Systems Inc., of Stratford, Conn., received patent No. 5,710,007, covering a new blood test that measures both total and free (non-complexed) forms of prostate specific antigen (PSA.).
EntreMed Inc., of Rockville, Md., received patent No. 5,720,921, covering the electroporation chamber, a core component of the company's cell permeation technology. The patent involves both the chamber and its method of use in incorporating drugs, genes, proteins and other substances into cells for therapeutic purposes.
Genetronics Biomedical Ltd., of San Diego, was awarded a patent for its electroporation and iontophoresis catheter with porous balloon. This application inserts drugs or genes directly into cells that might prevent reblockage of arteries. The device is inserted into a blood vessel where the inner wall needs to be treated. Electric pulses are then sent to the blood vessel wall, causing temporary pores to open and letting in the drug or gene into the cell's interior.